Current Status: Active PolicyStat ID: Origination: 04/2018 Effective: 04/2018 Approved: 04/2018 Last Revised: 04/2018 Expiration: 04/2021

Size: px
Start display at page:

Download "Current Status: Active PolicyStat ID: Origination: 04/2018 Effective: 04/2018 Approved: 04/2018 Last Revised: 04/2018 Expiration: 04/2021"

Transcription

1 Current Status: Active PolicyStat ID: Origination: 04/2018 Effective: 04/2018 Approved: 04/2018 Last Revised: 04/2018 Expiration: 04/2021 Owner: Policy Area: References: Suzanne Sharland-Hemmila: IRB Coordinator Institutional Review Board Applicability: U P Health Emergency/Compassionate Use or Single-Patient Use of Investigational Drugs, Biologics and/or Devices (IRB ) PURPOSE The purpose of this policy is to offer UP Health System-Marquette (UPHS-M) Institutional Review Board guidance on the use of an investigational drug, biologic and/or device in a life-threatening situation for us of compassionate reasons. SCOPE This policy applies to both internal and external research administrators, investigators, research staff, IRB members and IRB staff. DEFINITIONS Emergency Use is defined as the use of an investigational drug, biologic and/or device with a human subject in a life-threatening situation in which no standard acceptable treatment is available and in which there is not sufficient time to obtain IRB approval (21 CFR (d)). The emergency use provision in the FDA regulations is an exemption from prior review and approval by the IRB. The exemption, which may not be used unless all of the conditions described in 21 CFR (d) exist, allows for one emergency use of an investigational article without prospective IRB review. FDA regulations require that any subsequent use of the investigational article at the institution have prospective IRB review and approval. FDA acknowledges, however, that it would be inappropriate to deny emergency treatment to a second individual if the only obstacle is that the IRB has not had sufficient time to convene a meeting to review the issue. Life-threatening for the purpose of section (d), includes the scope of both life-threatening and severely debilitating, as defined below: (Serious) Life-threatening disease or condition means: (1) diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and (2) diseases or conditions with potentially fatal outcomes, where the endpoint of clinical trial analysis is survival. Severely debilitating means diseases or conditions that cause major irreversible morbidity. Examples of severely debilitating conditions include blindness, loss of arm, leg, hand or foot, loss of hearing, paralysis or stroke. Single- Patient Use (Compassionate) the phrase "compassionate use" is commonly used to describe some of the ways of making unapproved products available to patients; there is no FDA regulation or policy Page 1 of 6

2 defining "compassionate use." Compassion, intent to help, should be, and is, an element of all drug/biologic/ device investigation activities. In general, these uses of drug/biologic/devices are described as "treatment uses," because their intent is to provide treatment of patients, not primarily to evaluate the safety and effectiveness of the drug/biologic/devices, the primary and usual purpose of studies under an Investigational New Drug Application (IND). FDA refers to "compassionate use" requests for individual patients as a "single patient IND" study; wider use would usually take place under a "treatment IND" or "treatment protocol" under an existing commercial IND. A "single patient use" allows a physician to obtain access to an investigational drug/biologic/device for the treatment of a single patient. Usually, the patient is in a desperate situation and unresponsive to other therapies, or in a situation where no approved or generally recognized treatment is available. Further, there is usually little evidence that the proposed therapy is useful, but may be plausible on theoretical grounds or anecdotes of success. POLICY: "Emergency Use" of Investigational Drugs, Biologics and/or Devices It is the policy of U P Health System Marquette (UPHS-M) and the UPHS-M Institutional Review Board (IRB) to allow "emergency use of an investigational drug, biologic and/or device" providing regulatory criteria are met for an emergency use exemption, based on the following conditions: 1. Life-threatening situation or severely debilitating situation 2. No standard acceptable treatment available 3. Not sufficient time to obtain IRB approval 4. Report to the IRB within 5 working days of use 5. Any subsequent use of the test article is subject to IRB review 6. The activity is not a systematic investigation designed to develop or contribute to generalizable knowledge PROCEDURE: "Emergency Use" of Investigational Drugs, Biologics and/or Devices- The following will apply: Investigators will notify the IRB within five (5) working days of emergency use, even if the investigator notified the IRB prior to use and will include in the notification: 1. Justification for "emergency" use, 2. The consent document and process, 3. Why prospective reporting was not feasible (if applicable) 4. For investigational drugs, biologics and/or devices, documentation of FDA authorization pursuant to 21 CFR 312, Subpart I. The IRB chair or physician IRB member will evaluate whether the circumstances meet the criteria for the emergency use exemption and whether the informed consent process meets regulatory criteria and document their findings. Clarification may be obtained from the investigator if necessary. The IRB chair, physician IRB member, or an IRB administrator notifies the investigator of the determination once made. This notification should not be construed as IRB approval. If the investigator notified the IRB prior to use; the IRB chair, designated physician IRB member, or IRB administrator will initiate tracking to follow-up with the investigator to assure that the investigator files a report to the IRB within five (5) working days. If the investigator is not able to obtain informed consent of the subject or the subject's legally authorized Page 2 of 6

3 representative prior to emergency use of the investigational drug, biologic and/or device, the investigator's report must include a certification from a physician who is not otherwise participating in the clinical investigation as to how the use met the criteria for exception from informed consent in 21 CFR 50.23(a) (c). See details below under "Exception from Informed Consent Requirement." Reports of emergency use will be provided to the IRB at a regularly scheduled IRB meeting. Any noncompliance with the criteria for emergency use will be reviewed. If the activity is subject to U.S. Department of Health and Human Services regulations: Patients receiving an investigational drug, biologic and/or device in an emergency use as defined by FDA regulation may not be considered a research subject Data obtained from patients cannot be classified as human subject research Outcome of such care cannot be included in any report of research activity If the activity is subject to FDA regulations, emergency use of the investigational drug, biologic and/or device is considered to be a clinical investigation, the patient is a subject, and the FDA may require data from an emergency use to be reported in a marketing application. If the investigator plans subsequently to use the investigational article, he or she must submit an initial application to the IRB for review and approval prior to such use. Any subsequent use of the investigation article is subject to IRB review. Exception from Informed Consent Requirement Even for an emergency use, the investigator is required to obtain informed consent from the subject or the subject's legally authorized representative (LAR) in accordance with 21 CFR 50 (such as providing all required and appropriate additional elements of disclosure) and document consent in writing in accordance with 21 CFR (obtaining a signed and dated consent document consistent with the short or long form regulatory requirement) unless both the investigator and a physician who is not otherwise participating in the clinical investigation certify in writing all of the following (21 CFR 50.23(a)): 1. The human subject is confronted by a life-threatening situation necessitating the use of the investigational drug, biologic and/or device. 2. Informed consent cannot be obtained from the subject because of an inability to communicate with, or obtain legally effective consent from, the subject. 3. Time is not sufficient to obtain consent from the subject's legal representative. 4. There is no available alternative method of approved or generally recognized therapy that provides an equal or greater likelihood of saving the life of the subject. A report by the investigator and a physician who is not otherwise participating in the clinical investigation's written certification must be submitted to the IRB within five (5) working days after the use of the investigational drug, biologic and/or device. The IRB chair or designated physician IRB member will review the five (5) working day report to determine if the regulatory requirements in 21 CFR 50.23(a) have been met. If, in the investigator's opinion, immediate use of the investigational drug, biologic and/or device is required to preserve the subject's life, and if time is not sufficient to obtain an independent physician's determination that the four conditions above apply, the clinical investigator should make the determination and, within five (5) working days after the use of the drug, biologic and/or device, have the determination reviewed and evaluated in writing by a physician who is not participating in the clinical Page 3 of 6

4 investigation. 21 CFR 50.23(b). The independent evaluation must be submitted to the IRB within the five (5) working days' time period. 21 CFR 50.23(c). The IRB chair or designated physician IRB member will review the five (5) working day report to determine if the regulatory requirements in 21 CFR 50.23(a) 21 CFR 50.23(c) have been met. POLICY: "Single Patient Use" of Investigational Drugs, Biologics and/or Devices It is the policy of U P Health System Marquette (UPHS-M) and the UPHS-M Institutional Review Board to allow "single - patient use of an investigational drug, biologic and/or device" providing regulatory criteria are met based on the following conditions: 1. The patient is in a desperate situation and unresponsive to other therapies, or 2. The patient is in a situation where no approved or generally recognized treatment is available. 3. Further, there is usually little evidence that the proposed therapy is useful, but may be plausible on theoretical grounds or anecdotes of success. 4. Access to an investigational drug, biologic and/or device for use by a single, identified patient will be gained either through the sponsor under a treatment protocol, or through the FDA, by first obtaining the drug, biologic and/or device from the sponsor, and then submitting a treatment IND to the FDA requesting authorization to use the investigation drug, biologic and/or device for treatment use (21 CFR ) Submissions For Treatment Use PROCEDURE: "Single-Patient Use" of Investigational Drugs, Biologics and/or Devices Processing a Request for Single - Patient Use/Compassionate Use: 1. When a physician would like to treat an individual patient using an unapproved drug, biologic and/or device the physician should first ensure that the manufacturer of the unapproved drug, biologic and/or device is willing to provide the drug, biologic and/or device. If the manufacturer agrees to provide the drug, biologic and/or device, the physician should submit an IND to the FDA. 2. The criteria are the same for a Single Patient IND and Emergency Use IND, except that for an Emergency Use, there is insufficient time to obtain prior IRB approval. 3. FDA regulations 21 CFR and 21 CFR permits an investigational drug, biologic and/or device to be used for the treatment of an individual patient by a licensed physician, under the following circumstances. A. The patient has a serious or immediately life-threatening disease or condition; a. Immediately life-threatening disease or condition means a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment. b. Serious disease or condition means a disease or condition associated with morbidity that has substantial impact on day-to-day functioning. Short-lived and self-limiting morbidity will usually not be sufficient, but the morbidity need not be irreversible, provided it is persistent or recurrent. Whether a disease or condition is serious is a matter of clinical judgment, based on its impact on such factors as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one. B. There is not comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; Page 4 of 6

5 C. The potential patient benefit justifies the potential risks of the treatment use; D. The potential risks are not unreasonable in the context of the disease or condition to be treated; E. The probable risk to the patient from the investigational drug, biologic and/or device is not greater than the probable risk from the disease or condition F. The patient cannot obtain the drug, biologic and/or device under another IND or protocol; and G. Providing the investigational drug, biologic and/or device for the requested use will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the expanded access use or otherwise compromise the potential development of the expanded access use. Please refer to the FDA's website on "Physician Request for an Individual Patient IND under Expanded Access for Non-Emergency or Emergency Use" for more information. 4. If the situation satisfies the FDA criteria for single - patient use, the next step is to determine whether an IRB acknowledgment letter (versus an IRB approval letter) is what the sponsor requires. 5. If the situation fits the criteria for single - patient use and the sponsor requires an acknowledgement letter, follow these procedures for an emergency-use exemption as described: A. The investigator will generate a letter to the IRB chair describing the single patient use situation. The letter must document compliance with specific FDA requirements for emergency use as indicated in #3. (Sample Addendum #1) B. The notification to the IRB must occur before use of the investigational articles. C. The IRB chair or appropriate designee (IRB member with appropriate medical knowledge) reviews the investigator's letter and confirms that (1) an emergency situation exists and that (2) there is not sufficient time to convene a full-board IRB meeting. D. The IRB office generates a letter to be signed by the IRB chair (or designee) acknowledging notification of emergency use of the investigational article. (Sample Addendum #1) E. The IRB letter should indicate only knowledge of, acknowledgement of, or appropriate notification of the use of the investigational article. The IRB letter should not indicate IRB review or approval. F. All subsequent uses of the test article should be reviewed using the standard full-board IRB review process. If an investigator believes another request for the use of this investigational article is forthcoming, the full IRB review process should be initiated. The FDA acknowledges that subsequent uses should not be denied because the IRB could not convene in a timely manner. The IRB letter to the investigator should also describe the FDA subsequent-use requirement. G. If the situation does not meet FDA criteria for emergency use, a convened full-board IRB review and approval of the protocol and consent form per standard IRB review procedure must be completed before release of the investigational article. H. If the sponsor requires IRB approval before release of the investigational article, an IRB approval letter may only be written after a convened full-board review and approval of the protocol and the consent form according to standard IRB procedure. I. No type of expedited or subcommittee process is allowed for IRB review and approval of the emergency use of an investigational article, according to federal regulations. REFERENCES 21 CFR Documentation of Informed Consent 21 CFR Institutional Review Boards Page 5 of 6

6 21 CFR 312 Investigational and New Drug Application Policy Effective Date: 11/13/13 Policy Revisions: 07/15 Attachments: Compassionate Use Document- IRB docx Compassionate Use Letter IRB Chair to MD- IRB docx Compassionate Use Letter MD to IRB Chair-IRB docx Approval Signatures Step Description Approver Date Wael Khouli: Chief Medical Officer 04/2018 Rudolph Evonich: Physician 04/2018 Dianna Larson: Director of Research 04/2018 Suzanne Sharland-Hemmila: IRB Coordinator 04/2018 Applicability U P Health Page 6 of 6

EMERGENCY USE 03/02/2016

EMERGENCY USE 03/02/2016 DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program EMERGENCY USE 03/02/2016 Emergency Exemption for an Investigational Drug or Biologic or Unapproved Device Emergency use of an investigational

More information

Policy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013; 05/01/2016; 10/16/2018

Policy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013; 05/01/2016; 10/16/2018 University of California, Irvine Human Research Protections Standard Operating Policies and Procedures Policy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013;

More information

Date Effective 4/21/2008 Identification

Date Effective 4/21/2008 Identification OHSU Research Integrity Office Human Research Protection Program Policies & Procedures Title: Research with Medical Devices Date Effective 4/21/2008 Identification Supersedes P&P dated: Page 1 of BACKGROUND

More information

Reporting an Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO) to the IRB

Reporting an Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO) to the IRB INSTITUTIONAL REVIEW BOARD (IRB) OFFICE FOR HUMAN RESEARCH PROTECTION Reporting an Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO) to the IRB UPIRTSO Flowchart Content Applies To

More information

SOP Title Review of Research: Devices for Humanitarian Uses

SOP Title Review of Research: Devices for Humanitarian Uses SOP Title Review of Research: Devices for Humanitarian Uses Purpose This document describes the National Jewish Health IRB review of Humanitarian Use Devices and Humanitarian Device Exemptions. Scope Humanitarian

More information

IRB Training October 22, 2015

IRB Training October 22, 2015 Humanitarian Use Devices & Humanitarian Device Exemptions IRB Training October 22, 2015 What is a Humanitarian Use Device (HUD)? Intended to benefit patients in the treatment or diagnosis of diseases or

More information

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH I. PURPOSE This document outlines the required elements of University of Tennessee

More information

Initial Review. Approved By: Michele Kennett, JD, MSN, LLM Associate Vice Chancellor for Research. Table of Contents

Initial Review. Approved By: Michele Kennett, JD, MSN, LLM Associate Vice Chancellor for Research. Table of Contents Institutional Review Board University of Missouri-Columbia Standard Operating Procedure Initial Review Initial Review Effective Date: September 1, 2004 Original Approval Date: September 1, 2004 Revision

More information

CONTINUING REVIEW CRITERIA FOR RENEWAL

CONTINUING REVIEW CRITERIA FOR RENEWAL 1. POLICY Steering Committee approved / Effective Date: 9/2/15 The IRB conducts continuing review of research taking place within its jurisdiction at intervals appropriate to the degree of risk, but not

More information

Investigator Manual. If you have questions about whether an activity requires IRB review, contact the IRB Office.

Investigator Manual. If you have questions about whether an activity requires IRB review, contact the IRB Office. CM-999 001 1 May 2015 Page 1 of 5 What is the purpose of this manual? This document is designed to guide you through policies and procedures related to the conduct of human research that are specific to

More information

Yale University Human Research Protection Program

Yale University Human Research Protection Program Yale University Human Research Protection Program HRPP Policy 700 Noncompliance, Suspension and Termination Responsible Office Office of Research Administration Effective Date: February 10, 2009 Responsible

More information

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH I. PURPOSE This document outlines the University of Tennessee Health Science Center Institutional

More information

OHRP Guidance on Written IRB Procedures

OHRP Guidance on Written IRB Procedures Office for Human Research Protections (OHRP) Department of Health and Human Services Date: OHRP Guidance on Written IRB Procedures Scope: This document outlines the required elements of written Institutional

More information

Effective Date: January 16, 2012 Policy Number: MHC_RP0107. Revised Date: November 2, 2015 Oversight Level: Corporate

Effective Date: January 16, 2012 Policy Number: MHC_RP0107. Revised Date: November 2, 2015 Oversight Level: Corporate Policy Title: Initial Review of Human Subject Research Effective Date: January 16, 2012 Policy Number: Review Date: November 20, 2015 Section: Revised Date: November 2, 2015 Oversight Level: Corporate

More information

Study Management SM STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB)

Study Management SM STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB) Study Management SM 302.00 STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB) Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval:

More information

CONTINUING REVIEW 3/7/2016

CONTINUING REVIEW 3/7/2016 DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program Introduction CONTINUING REVIEW 3/7/2016 Federal regulations require that DUHS has written procedures which the IRB will follow for (a) conducting

More information

Humanitarian Use Devices Made Simple

Humanitarian Use Devices Made Simple May 25, 2017 Humanitarian Use Devices Made Simple Robert Romanchuk, BSHS, CIP, CCRC, CHRC, CCRCP IRB Vice Chairperson, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA

More information

CONTINUING REVIEW CRITERIA FOR RENEWAL

CONTINUING REVIEW CRITERIA FOR RENEWAL 1. POLICY Steering Committee approved / Effective Date: 9/2/19/19/11 The IRB conducts continuing review of research taking place within its jurisdiction at intervals appropriate to the degree of risk,

More information

SOP 801: Investigator Qualifications and Responsibilities

SOP 801: Investigator Qualifications and Responsibilities 1. POLICY University of Oklahoma : Investigator Qualifications and Responsibilities The purpose of this policy is to outline the qualifications and responsibilities of the principal investigator and key

More information

I. Summary. II. Responsibilities

I. Summary. II. Responsibilities IRB Procedures 9a: Full review procedures Revision date: October 6, 2008, revision November 11, 2009, revision July 17, 2010, revised January 27, 2011, revised February 9, 2015, revised October 15, 2015

More information

HUD and HDE Topics. Humanitarian Use Device and. Humanitarian Use Device. Humanitarian Device Exemption

HUD and HDE Topics. Humanitarian Use Device and. Humanitarian Use Device. Humanitarian Device Exemption Humanitarian Use Device Humanitarian Device Exemption Marian Serge, RN Division of Bioresearch Monitoring Center for Devices and Radiological Health Marian.Serge@fda.hhs.gov 1 HUD and HDE Topics Regulations//Guidance

More information

What s New in GCP? FDA, OHRP Issue Harmonized Guidance on Transferring IRB Oversight of Clinical Studies

What s New in GCP? FDA, OHRP Issue Harmonized Guidance on Transferring IRB Oversight of Clinical Studies Vol. 8, No. 8, August 2012 Happy Trials to You What s New in GCP? FDA, OHRP Issue Harmonized Guidance on Transferring IRB Oversight of Clinical Studies Reprinted from the Guide to Good Clinical Practice

More information

SOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS

SOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS University of Oklahoma Office of Human Research Participant Protection : PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS 1. POLICY Protocol deviations and unanticipated problems may be discovered in a variety

More information

IRB Chair Responsibilities

IRB Chair Responsibilities IRB Chair Responsibilities Introduction: The Saint Luke s Health System (SLHS) Institutional Review Board (IRB) Human Research Protection Program (HRPP) is guided by the ethical principles regarding research

More information

Signature Date Date First Effective: Signature Date Revision Date: 07/18/2011

Signature Date Date First Effective: Signature Date Revision Date: 07/18/2011 University of Kentucky Office of Research Integrity and Institutional Review Board Revision #4 TITLE: HIPAA in Research Page 1 of 8 Approved By: ORI Director Signature Date Date First Effective: 06-10-05

More information

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES TITLE: SUSPENSION OR TERMINATION OF IRB APPROVAL DOCUMENT NUMBER: 029 REVISION NUMBER 02 REVISION DATE (SUPERSEDES PRIOR

More information

To assure knowledge and compliance by documenting the continuing review procedure of approved projects for the IRB.

To assure knowledge and compliance by documenting the continuing review procedure of approved projects for the IRB. Institutional Review Board.... University of Missouri-Columbia.. Standard Operating Procedure Continuing Review Report (CRR) Continuing Review Report (CRR) Effective Date: July 1, 2004 Original Approval

More information

To assure knowledge and compliance by documenting the annual administrative review and continuing IRB review of non-exempt projects for the IRB.

To assure knowledge and compliance by documenting the annual administrative review and continuing IRB review of non-exempt projects for the IRB. Institutional Review Board.... University of Missouri-Columbia.. Standard Operating Procedure Annual Review of Research Annual Review of Research Effective Date: January 21, 2019 Original Approval Date:

More information

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures. IRB Review Processes

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures. IRB Review Processes Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this standard operating procedure is to describe IRB review processes, including pre-review, review, and post-review procedures. POLICY STATEMENT The

More information

Procedure Department: HUMAN RESEARCH PROTECTIONS PROGRAM Policy Number: II.B.1

Procedure Department: HUMAN RESEARCH PROTECTIONS PROGRAM Policy Number: II.B.1 Procedure Department: HUMAN RESEARCH PROTECTIONS PROGRAM Policy Number: II.B.1 Section: HRPP Compliance Review Responsibility: HRPP Policy and Procedure Committee Original Creation Dare: November 1, 2003

More information

Michigan State University Human Research Protection Program

Michigan State University Human Research Protection Program Subject: Noncompliance Section: 9-2 Michigan State University Human Research Protection Program This policy and procedure supersedes those previously drafted. Approved by: Vice President of Research and

More information

Florida State University IRB Standard Operational Procedures

Florida State University IRB Standard Operational Procedures Florida State University IRB Standard Operational Procedures 7-IRB-12 Title of Standard Operational Procedure: Cooperative Project/Multi-site projects IRB Review Responsible Executive: Approving Official:

More information

Effective Date Revisions Date Review by the Convened Institutional Review Board

Effective Date Revisions Date Review by the Convened Institutional Review Board Review by the Convened Institutional Review Board Effective Date Revisions Date 8.1.2018 1.0 Purpose: The purpose of this standard operating practice (SOP) is to define and describe the process of review

More information

Supersedes Document Dated: 7/7/11. SOP: RR 401 Version No.: 07 Version Date: 9/8/15 EXPEDITED REVIEW 1. POLICY

Supersedes Document Dated: 7/7/11. SOP: RR 401 Version No.: 07 Version Date: 9/8/15 EXPEDITED REVIEW 1. POLICY 1. POLICY Steering Committee approved / Effective Date: 9/9/15 An expedited review procedure consists of a review of research involving human subjects by an IRB Chair or by one or more experienced reviewers

More information

SUSPENSION OR TERMINATION OF HUMAN SUBJECTS RESEARCH

SUSPENSION OR TERMINATION OF HUMAN SUBJECTS RESEARCH P&P: RR 409 Version No:1.2 Effective Date: 11/20/2013 SUSPENSION OR TERMINATION OF HUMAN SUBJECTS RESEARCH Supercedes: CPHS Policies and Procedures 11/28/2000 1. POLICY The IRB shall have authority to

More information

HSPP Standard Operating Procedures

HSPP Standard Operating Procedures HSPP Standard Operating Procedures General HRP 001 Definitions HRP 012 Observation of Consent Process HRP 013 Legally Authorized Representatives, Children, and Guardians Management of Incoming Information

More information

IRB MEETING ADMINISTRATION

IRB MEETING ADMINISTRATION 1. POLICY Steering Committee approved / Effective date: 9/11/15 Except when an expedited review procedure is appropriate or an exemption determination may be made, the IRB will review proposed research

More information

Review of Research by the Convened IRB

Review of Research by the Convened IRB Office for the Protection of Research Subjects (OPRS) Institutional Review Board FWA# 00000083 Review of Research by the Convened IRB 201 AOB (MC 672) 1737 West Polk Street Chicago, IL 60612-7227 Phone:

More information

Signature Date Date First Effective: Signature Date Revision Date:

Signature Date Date First Effective: Signature Date Revision Date: Revision #10 TITLE: Continuation Review Page 1 of 10 Approved By: ORI Director Signature Date Date First Effective: 05-17-05 Approved By: Nonmedical IRB Chair Signature Date Approved By: Medical IRB Chair

More information

EXPEDITED REVIEW. Terms used in this policy, but not defined herein shall have the meanings set forth in the Glossary.

EXPEDITED REVIEW. Terms used in this policy, but not defined herein shall have the meanings set forth in the Glossary. 1. POLICY Steering Committee approved / Effective Date: 9/19/11 An expedited review procedure consists of a review of research involving human subjects by an IRB Chair or by one or more experienced reviewers

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Page 1 of 6 POLICY CONTINUING REVIEW BY THE IRB The University of Cincinnati Institutional Review Board (IRB) shall conduct continuing review of human participant research at intervals appropriate to the

More information

SOP 5.06 Full Committee Review: Initial IRB Review

SOP 5.06 Full Committee Review: Initial IRB Review Office of Research Integrity - Human Subjects SOP #: ORI-HS(HS)- Page #: Page 1 of 5 Approved By: ORI-HS Executive Director *Signature on file Date: Date First Effective: 10/13/2016 Approved by: Biomedical

More information

7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL

7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL 7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL 7.1 OBJECTIVE To describe the policies and procedures for reviewing a modification or a deviation/exception to a previously approved protocol.

More information

NONCOMPLIANCE. 1. Overview

NONCOMPLIANCE. 1. Overview NONCOMPLIANCE 1. Overview Investigators, research staff, the IRBs, (ORRP), and the organization share responsibility for the ethical conduct of human subjects research and for compliance with federal regulations,

More information

Independent Ethics Committees

Independent Ethics Committees GCP Independent Ethics Committees 1 GCP What is an Ethics Committee? An ethics committee is a committee formally designated to review and approve the initiation of a clinical research study involving human

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Inspections, Compliance, Enforcement, and Criminal Investigations Burzynski Research Institute / IRB Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,

More information

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Post-Approval Submissions

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Post-Approval Submissions Reliance Agreement Guidance: Post-Approval Submissions This document is designed to provide guidance on the requirements and submission processes for Amendments, Continuing Review, Reportable Events, and

More information

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Continuing Review of Approved Research

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Continuing Review of Approved Research Page: 1 of 6 I. PURPOSE The purpose of this SOP is to describe the submission requirements for investigators and the review requirements for the IRB for the conduct of continuing review in accordance with

More information

21 CFR Part 56 - Institutional Review Boards

21 CFR Part 56 - Institutional Review Boards INFORMATION SHEETS Guidance for Institutional Review Boards and Clinical Investigators 1998 Update Appendix C 21 CFR Part 56 - Institutional Review Boards Subpart A General Provisions 56.101 Scope. 56.102

More information

Wayne State University Institutional Review Board

Wayne State University Institutional Review Board Wayne State University Institutional Review Board Subject Approvals, Serious & Continuing Non-Compliance and the Institutional Official s Responsibilities Administrative Approval: 07/2011; Office of the

More information

JUN L WARNING LETTER VIA FEDERAL EXPRESS

JUN L WARNING LETTER VIA FEDERAL EXPRESS DEPARTMENT OF HEALTH, & HUMAINi SEF.'`viLES JUN L 2 2006., WARNING LETTER VIA FEDERAL EXPRESS Patricia Hardenbergh, MD Chairperson, Vail Valley Medical Center IRB 181 West Meadow Drive, Suite 100 Vail,

More information

(y9. &i?r, JUL t Certified-Return Receipt Requested WARNING LE7TER

(y9. &i?r, JUL t Certified-Return Receipt Requested WARNING LE7TER ... (y9 &i?r, DEPARTMENT OF HEALTH a HUMAN SERVICES Public Health Service Food and Drug Admini~ation Center for Biologics Evaluation and Rem 1401 Rockville Pike Rockville MD 20852-1448 JUL t 71997 Certified-Return

More information

the HRPP Director will prepare a draft report within three (3) workdays after the IRB meeting at which the determination occurred.

the HRPP Director will prepare a draft report within three (3) workdays after the IRB meeting at which the determination occurred. IRB Policy 34: Reporting Policy Revision Date: March 27, 2009, revised June 11, 2010, revised January 27, 2011, revised 9/23/13, revised 9/17/15, revised 4/2/18, revised 9/14/18 INSTITUTIONAL REVIEW BOARD

More information

RESEARCH SUBMISSION REQUIREMENTS

RESEARCH SUBMISSION REQUIREMENTS 1. POLICY IRB members rely primarily solely on the documentation submitted by investigators for initial and continuing review. Therefore this material must provide IRB members with enough information about

More information

Human Research Protections Program Medical College of Wisconsin and Froedtert Memorial Lutheran Hospital

Human Research Protections Program Medical College of Wisconsin and Froedtert Memorial Lutheran Hospital Human Research Protections Program Medical College of Wisconsin and Froedtert Memorial Lutheran Hospital To Whom It May Concern: The Medical College of Wisconsin (MCW) has an approved Federal Wide Assurance

More information

UNIVERSITY OF GEORGIA Institutional Review Board

UNIVERSITY OF GEORGIA Institutional Review Board UNIVERSITY OF GEORGIA Institutional Review Board Continuing Review Number: Date: Author: Approved By: Page(s): UGAHRP-057-2 01/20/2017 HSO IRB Page 1 of 7 1. PURPOSE 1.1. The UGA IRB has developed this

More information

AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016

AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016 DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016 The Duke University Health System Institutional Review Board (DUHS IRB) requires that

More information

DOCUMENTATION OF IRB DISCUSSIONS AND DECISIONS ( IRB MINUTES)

DOCUMENTATION OF IRB DISCUSSIONS AND DECISIONS ( IRB MINUTES) POLICY # RESEARCH POLICY & PROCEDURE Approval Date: 12-19-2008 CTM Review Cycle: 1 2 3 Revision Dates: AAHRPP DOC # 54 Responsible Office: Research Compliance DOCUMENTATION OF IRB DISCUSSIONS AND DECISIONS

More information

Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval

Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval Additional copies are available from: Office of Communication Division of Drug Information,

More information

Standard Operating Policy and Procedures (SOPP) 3:

Standard Operating Policy and Procedures (SOPP) 3: Standard Operating Policy and Procedures (SOPP) 3: INITIAL AND CONTINUING REVIEW BY THE IRB: REQUIREMENTS FOR SUBMISSION OF APPLICATIONS, APPROVAL CRITERIA, EXPEDITED AND CONVENED COMMITTEE REVIEW AND

More information

Administrative Hold, Suspension, or Termination of IRB Approval

Administrative Hold, Suspension, or Termination of IRB Approval Office for the Protection of Research Subjects (OPRS) Institutional Review Board FWA# 00000083 Administrative Hold, Suspension, or Termination of IRB Approval 201 AOB (MC 672) 1737 West Polk Street Chicago,

More information

Institutional Review Board Standard Operating Procedure. Suspension and Termination of IRB Approval

Institutional Review Board Standard Operating Procedure. Suspension and Termination of IRB Approval Institutional Review Board Standard Operating Procedure University of Missouri-Columbia Suspension and Termination of IRB Approval Effective Date: May 31, 2006 Original Approval Date: May 31, 2006 Revision

More information

Issue in IRB Approvals:

Issue in IRB Approvals: Issue in IRB Approvals: What are the obligations of investigators and the IRB in maintaining IRB approval? What are the consequences of a lapse in IRB approval? How does the IRB evaluate lapses in approval?

More information

INSTITUTIONAL REVIEW BOARD (IRB) PROCEDURES

INSTITUTIONAL REVIEW BOARD (IRB) PROCEDURES INSTITUTIONAL REVIEW BOARD (IRB) PROCEDURES July 2016 Table of Contents National American University Mission...2 Purposes...2 Core Values...3 Institutional Review Board Policy...4 IRB Membership...6 Training...7

More information

Section 8. Continuing Review of Ongoing IRB-Approved Research (Revised 7/1/10)

Section 8. Continuing Review of Ongoing IRB-Approved Research (Revised 7/1/10) Section 8 Continuing Review of Ongoing IRB-Approved Research (Revised 7/1/10) The IRB shall conduct continuing review of all research activity in compliance with 45 CFR 46 and 21 CFR 56. Continuing review

More information

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: How to Apply for External IRB Review

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: How to Apply for External IRB Review Reliance Agreement Guidance: How to Apply for External IRB Review This document provides step by step instructions on how to submit a request for the Penn IRB to rely on an External IRB using the HS-ERA

More information

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD PROCEDURES FOR FULL BOARD REVIEW

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD PROCEDURES FOR FULL BOARD REVIEW UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD PROCEDURES FOR FULL BOARD REVIEW I. PURPOSE This document outlines the required elements of Institutional Review Board (IRB)

More information

Illinois Institute of Technology Institutional Review Board Handbook of Procedures for the Protection of Human Research Subjects

Illinois Institute of Technology Institutional Review Board Handbook of Procedures for the Protection of Human Research Subjects Illinois Institute of Technology Institutional Review Board Handbook of Procedures for the Protection of Human Research Subjects The Basics of Human Subject Research Protection Federal regulation (Title

More information

WORKING WITH THE INSTITUTIONAL REVIEW BOARD &

WORKING WITH THE INSTITUTIONAL REVIEW BOARD & WORKING WITH THE INSTITUTIONAL REVIEW BOARD & October 17, 2018 @ Noon (Classroom PRIVACY 8B): BOARD Diann Johnson, MPH Associate IRB Administrator October 26, 2018 @ Noon (Perrin Long Library B6-508):

More information

Yale University Institutional Review Boards

Yale University Institutional Review Boards Yale University Institutional Review Boards 100 PR.1 Review by a Convened Institutional Review Board (IRB) Overview... 1 Meeting Dates and Distribution of Materials... 1 Materials Provided to Members for

More information

2.0 Institutional Review Board

2.0 Institutional Review Board 2.0 Institutional Review Board 2.1 Policy Pennington Biomedical Research Center has one IRB to ensure the protection of human subjects in research. IRB Biomedical (IRB 00000708) (IORG00006218) The IRB

More information

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Penn as Central IRB FAQ

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Penn as Central IRB FAQ Reliance Agreement Guidance: Penn as Central IRB FAQ This document is designed to answer questions frequently asked by individuals who want to know more about Penn s policies and procedures related to

More information

University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP)

University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP) University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP) I. OVERVIEW The purpose of this Standard Operating Procedure is to define a process for all University of Iowa

More information

This policy defines the composition and requirements of the North Shore Medical Center (NSMC) Institutional Review Board (IRB) membership.

This policy defines the composition and requirements of the North Shore Medical Center (NSMC) Institutional Review Board (IRB) membership. THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES Title: IRB Composition and Roster Page: 1 of 6 Written by: Laura W. Knight, MPH; Sr. IRB Administrator IRB Policy

More information

I. Summary. II. Responsibilities

I. Summary. II. Responsibilities IRB Procedure 11a: Continuing Review Revision Date: May 15, 2007, revised November 11, 2009, revision July 17, 2010, revised March 1, 2011, revised February 9, 2015 I. Summary The IRB policy is to make

More information

Research Involving Human Subjects: AA 110.7

Research Involving Human Subjects: AA 110.7 Research Involving Human Subjects: AA 110.7 Purpose To set forth certain human subjects rights and protections, and to establish a review process intended to ensure compliance with federal regulations

More information

SOP #2-2 Version #1 Date First Effective: December 14, Page 1 of 6

SOP #2-2 Version #1 Date First Effective: December 14, Page 1 of 6 Page 1 of 6 OBJECTIVE To describe policies and procedures for all types of protocol submissions that require review by the IRB after investigators receive initial approval. This includes protocol submissions

More information

MISSISSIPPI STATE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM. Collaborative Research and Performance Sites (01-23) Approved

MISSISSIPPI STATE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM. Collaborative Research and Performance Sites (01-23) Approved MISSISSIPPI STATE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM Collaborative Research and Performance Sites (01-23) Approved 02-04-2013 Policy It is the policy of the MSU HRPP that all human subjects research

More information

Screening and Enrollment Log. List of all subjects screened and all subjects screened and enrolled in the study.

Screening and Enrollment Log. List of all subjects screened and all subjects screened and enrolled in the study. Contents Screening and Enrollment Log... 2 Regulatory Approval... 3 Protocol, Amendments and Signature Pages... 4 Investigational Product Information - 1... 5 Investigational Product Information - 2...

More information

USC Institutional Review Boards (IRBs)

USC Institutional Review Boards (IRBs) Chapter 6: Chapter Contents 6.1 Description of USC IRBs USC Institutional Review Boards (IRBs) 6.2 The Membership of the IRB Committees 6.3 IRB Member Requirements 6.4 IRB Use of Consultants 6.5 IRB Support

More information

Baptist Health Institutional Review Board. Study Closure Report (Expedited Review) IRB #: Study Title:

Baptist Health Institutional Review Board. Study Closure Report (Expedited Review) IRB #: Study Title: Baptist Health Institutional Review Board Study Closure Report (Expedited Review) (Please complete ALL sections of this form. Incomplete forms will be returned) Principal Investigator: E-mail: Phone #:

More information

Chapter 4 Institutional Review Board (IRB) Roles and Authorities

Chapter 4 Institutional Review Board (IRB) Roles and Authorities Chapter 4 Institutional Review Board (IRB) Roles and Authorities HSS Institutional Review Board Guidance An Institutional Review Board (IRB) is an appropriately constituted group that has been formally

More information

The Children s Hospital of Philadelphia Committee for the Protection of Human Subjects Policies and Procedures. Cooperative Agreements

The Children s Hospital of Philadelphia Committee for the Protection of Human Subjects Policies and Procedures. Cooperative Agreements Page: 1 of 8 I. PURPOSE This standard operating procedure describes the IRB s procedures for review and oversight of research conducted under a cooperative agreement with an external (outside) IRB. It

More information

1. Review and approval of the consent document is a responsibility that FDA assigns to the IRB with jurisdiction

1. Review and approval of the consent document is a responsibility that FDA assigns to the IRB with jurisdiction Medical College of Wisconsin/Froedtert Hospital Guidance on Negotiating Consent Document Language For Clinical Trial Sponsors 1. Review and approval of the consent document is a responsibility that FDA

More information

SOP Institutional Review Board (IRB) Appointments and Membership

SOP Institutional Review Board (IRB) Appointments and Membership Office of Research Integrity - Human Subjects SOP #: ORI(HS)-3.06 Page #: Page 1 of 5 Approved By: ORI Executive Director Approved by: Biomedical Chair *Signature on File Date: Date First Effective: 01/25/2017

More information

Version 1. Submission Guide and Policies

Version 1. Submission Guide and Policies Submission Guide and Policies Pearl IRB Investigator Manual Table of Contents 1.1 Pearl IRB overview... 3 1.2 What is the purpose of this manual?... 3 1.3 What is Human Research?... 3 1.4 What is the Human

More information

University of Cincinnati. Radiation Safety Committee Operations Guidelines Statement of Policy (RSC Guidelines) RSC Guidelines (revision 5)

University of Cincinnati. Radiation Safety Committee Operations Guidelines Statement of Policy (RSC Guidelines) RSC Guidelines (revision 5) University of Cincinnati Radiation Safety Committee Operations Guidelines Statement of Policy (RSC Guidelines) Table of Contents 1 Purpose of the Guidelines 1 2 Committee 1 3 Meetings 4 4 Committee Purpose,

More information

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES 02 06/30/10 08/01/07 1 OF 6

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES 02 06/30/10 08/01/07 1 OF 6 TITLE: IRB CONTINUING REVIEW REVISION NUMBER SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES REVISION DATE (SUPERSEDES PRIOR VERSION) EFFECTIVE DATE DOCUMENT NUMBER:

More information

IRB COMPOSITION AND IRB MEMBER ROLES AND RESPONSIBILITIES

IRB COMPOSITION AND IRB MEMBER ROLES AND RESPONSIBILITIES IRB COMPOSITION AND IRB MEMBER ROLES AND RESPONSIBILITIES 1. Overview Each IRB must be appropriately constituted for the volume and types of human research to be reviewed, in accordance with federal regulations.

More information

Arkansas Tech University Institutional Review Board

Arkansas Tech University Institutional Review Board Arkansas Tech University Institutional Review Board Presentation Agenda IRB 1001: The Basics Levels of IRB Review IRB Decisions The Process of Consent Open Discussion IRB 1001: The Basics Human Participant

More information

AUTHORITY AND PURPOSE

AUTHORITY AND PURPOSE AUTHORITY AND PURPOSE SOP #: 101 VERSION #: 1 THIS POLICY PERTAINS TO: RESPONSIBILITY FOR EXECUTING POLICY: EFFECTIVE DATE: 5/1/09 ALL ACTIVITIES OF THE IRB SUPERSEDES DOCUMENT: IRB STAFF, IRB CHAIRPERSON,

More information

Single IRB Review. Jeannie Barone Director, HRPO. Institutional Review Board

Single IRB Review. Jeannie Barone Director, HRPO. Institutional Review Board Single IRB Review Jeannie Barone Director, HRPO Presentation Agenda New NIH policy Requests for Single IRB review Investigator vs. institutional responsibilities Current Regulations 45 CFR 46.111 (DHHS):

More information

CONTINUING REVIEW OF APPROVED IRB PROTOCOLS

CONTINUING REVIEW OF APPROVED IRB PROTOCOLS POLICY # RESEARCH POLICY & PROCEDURE Approval Date: 4-13-2012 CTM c Review Cycle: 1 2 3 Revision Dates: AAHRPP DOC # 64 Responsible Office: CONTINUING REVIEW OF APPROVED IRB PROTOCOLS Research Compliance

More information

Centralized IRB Models

Centralized IRB Models Centralized IRB Models NWABR / OHRP Conference July 31, 2014 James Riddle, MCSE, CIP, CPIA Assistant Director, Institutional Review Office Fred Hutchinson Cancer Research Center Outline Central IRB s Why

More information

IRB MEETING ADMINISTRATION

IRB MEETING ADMINISTRATION 1. POLICY Steering Committee approved / eeffective date: 8/31/15 4/6/11 Except when an expedited review procedure is used appropriate or an exemption determination may be madea study is deemed exempt,

More information

IV. Basic Procedures for Human Research Protections

IV. Basic Procedures for Human Research Protections Human Research Protection Program Procedures IV. Basic Procedures for Human Research Protections D. IRB Membership [45CFR46.107] (21CFR56.107) (1) General considerations The IRB shall have at least twelve

More information

Signature Date Date First Effective: Signature Date Revision Date: 05/14/2014

Signature Date Date First Effective: Signature Date Revision Date: 05/14/2014 Page 1 of 6 Approved By: ORI Director Signature Date Date First Effective: 06-28-05 Approved By: Nonmedical IRB Chair Signature Date Approved By: Medical IRB Chair Signature Date Revision Date: 05/14/2014

More information

Ceded IRB Review. The project involves prisoners or other vulnerable populations that require special considerations.

Ceded IRB Review. The project involves prisoners or other vulnerable populations that require special considerations. The first assessment to make when including collaborators in research is whether the collaborating entity is engaged in research (see OHRP s Guidance on Engagement in Research). IRB oversight of engaged

More information

POLICY NO EXEMPT RESEARCH... 4 POLICY NO DISCLOSURE OF RESEARCH LAB TEST RESULTS... 5

POLICY NO EXEMPT RESEARCH... 4 POLICY NO DISCLOSURE OF RESEARCH LAB TEST RESULTS... 5 Table of Contents POLICY NO. 101.01 - EXEMPT RESEARCH... 4 POLICY NO. 101.02 - DISCLOSURE OF RESEARCH LAB TEST RESULTS... 5 POLICY NO. 101.03 - IRB REVIEW OF HUMAN SUBJECTS RESEARCH... 6 POLICY NO. 101.04

More information